[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oht---ocular-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oht---ocular-hypertension":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100620199",false,"NCT07354516","Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension","Firecrest","Inclusion Criteria:\n\n* BCVA 1.0 logMAR or better in each eye (equivalent to 20\u002F200)\n* Diagnosis of mild to moderate OAG or OHT in at least one eye\n* IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG\u002FOHT\n* Prior use of any topical PGA without a clinically meaningful response\n* Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study\n* Use of other topical ocular concomitant medications 30 days prior\n* History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.\n* Central corneal thickness in either eye \\\u003C470 or \\>630 μm\n* Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.\n* Participation in any investigational study within 30 days prior to Screening\n* Females who are pregnant, nursing, or not using birth control.","ALL","12 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \\[PF\\], fixed-dose combination \\[FDC\\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).",[27,28],"OAG - Open-Angle Glaucoma","OHT - Ocular Hypertension",[30,31,32],"glaucoma","intraocular pressure (IOP)","eye drops","RECRUITING","2026-03-30",{"date":36,"type":37},"2026-04-03","ACTUAL",{"date":39,"type":37},"2026-03-18",{"date":41,"type":20},"2026-07-15",{"name":43,"class":44},"Qlaris Bio, Inc.","INDUSTRY",""]